文献速递肾移植

肾移植受者中的供者特异性抗体

Donor-Specific Antibodies in Kidney Transplant Recipients.
PubMed 文献 · Clin J Am Soc Nephrol · 2017-04-26

供者特异性抗体是预测抗体介导排斥反应的既定生物标志物,而抗体介导排斥反应是肾移植后移植物丢失的主要原因。移植后不同时间点和供者特异性抗体特征决定多种排斥表型,补体结合能力检测有助于预测排斥表型并指导临床实践。

要点

  • 供者特异性抗体是预测抗体介导排斥反应的关键生物标志物。
  • 预存供者特异性抗体可引发超急性、加速性急性及早期急性排斥。
  • 补体结合能力与IgG亚类有助于区分急性与慢性排斥表型。

核心结论

  • 深入理解供者特异性抗体的复杂特征可对患者免疫风险分层并预测不同抗体介导排斥反应表型。

主要发现

  • 预存供者特异性抗体在致敏患者中可触发超急性排斥、加速性急性排斥和早期急性抗体介导排斥。
  • 新生供者特异性抗体与晚期急性抗体介导排斥、慢性抗体介导排斥和移植肾小球病相关。
  • 补体结合供者特异性抗体与急性抗体介导排斥、更严重移植物损伤和早期移植物失败密切相关。
  • 非补体结合供者特异性抗体与亚临床或慢性抗体介导排斥及晚期移植物丢失相关。
  • 补体结合IgG3供者特异性抗体常与急性抗体介导排斥和严重移植物损伤相关,非补体结合IgG4则与亚临床或慢性抗体介导排斥及移植肾小球病更相关。

临床怎么用

  • 利用供者特异性抗体的抗原类别、特异性、强度、IgG亚类和补体结合能力等特征进行免疫风险分层。
  • 通过补体结合能力检测预测抗体介导排斥反应的不同表型。
  • 根据供者特异性抗体特征指导临床实践以改善移植结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Donor-specific antibodies have become an established biomarker predicting antibody-mediated rejection. Antibody-mediated rejection is the leading cause of graft loss after kidney transplant. There are several phenotypes of antibody-mediated rejection along post-transplant course that are determined by the timing and extent of humoral response and the various characteristics of donor-specific antibodies, such as antigen classes, specificity, antibody strength, IgG subclasses, and complement binding capacity. Preformed donor-specific antibodies in sensitized patients can trigger hyperacute rejection, accelerated acute rejection, and early acute antibody-mediated rejection. De novo donor-specific antibodies are associated with late acute antibody-mediated rejection, chronic antibody-mediated rejection, and transplant glomerulopathy. The pathogeneses of antibody-mediated rejection include not only complement-dependent cytotoxicity, but also complement-independent pathways of antibody-mediated cellular cytotoxicity and direct endothelial activation and proliferation. The novel assay for complement binding capacity has improved our ability to predict antibody-mediated rejection phenotypes. C1q binding donor-specific antibodies are closely associated with acute antibody-mediated rejection, more severe graft injuries, and early graft failure, whereas C1q nonbinding donor-specific antibodies correlate with subclinical or chronic antibody-mediated rejection and late graft loss. IgG subclasses have various abilities to activate complement and recruit effector cells through the Fc receptor. Complement binding IgG3 donor-specific antibodies are frequently associated with acute antibody-mediated rejection and severe graft injury, whereas noncomplement binding IgG4 donor-specific antibodies are more correlated with subclinical or chronic antibody-mediated rejection and transplant glomerulopathy. Our in-depth knowledge of complex characteristics of donor-specific antibodies can stratify the patient's immunologic risk, can predict distinct phenotypes of antibody-mediated rejection, and hopefully, will guide our clinical practice to improve the transplant outcomes.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Zhang R. Donor-Specific Antibodies in Kidney Transplant Recipients. Clin J Am Soc Nephrol. 2017. PMID: 28446536. doi:10.2215/CJN.00700117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。